Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:5,000Price:$0.08
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:5,000Price:$0.09
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Timourian, James GregoryOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:90 - Change in the nature of ownership# or value acquired/disposed of:30,000Price:$0.10
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:5,000Price:$0.10
-
Mar 06, 2024 (filed on Mar 13, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:3,000Price:$0.09
-
Mar 04, 2024 (filed on Mar 04, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:3,000Price:$0.10
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:1,000Price:$0.08
-
Feb 29, 2024 (filed on Mar 01, 2024)Insider Name:Milne, CraigOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:6,000Price:$0.08
-
Feb 22, 2024 (filed on Feb 22, 2024)Insider Name:Boone, TylerOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:20,000Price:$0.09
-
Feb 22, 2024 (filed on Feb 22, 2024)Insider Name:Boone, TylerOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:51 - Exercise of options# or value acquired/disposed of:20,000Price:$0.05
Filings by filing date
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:5,000Price:$0.08
-
Mar 18, 2024 (filed on Mar 18, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:5,000Price:$0.09
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Timourian, James GregoryOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:90 - Change in the nature of ownership# or value acquired/disposed of:30,000Price:$0.10
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:5,000Price:$0.10
-
Mar 06, 2024 (filed on Mar 13, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:3,000Price:$0.09
-
Mar 04, 2024 (filed on Mar 04, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:3,000Price:$0.10
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Savage, Alan Clyde HayesOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:1,000Price:$0.08
-
Feb 29, 2024 (filed on Mar 01, 2024)Insider Name:Milne, CraigOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:6,000Price:$0.08
-
Feb 21, 2024 (filed on Feb 26, 2024)Insider Name:Milne, CraigOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:10 - Acquisition or disposition in the public market# or value acquired/disposed of:3,000Price:$0.75
-
Feb 22, 2024 (filed on Feb 22, 2024)Insider Name:Boone, TylerOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:20,000Price:$0.09
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 2011 94 St NW Suite 101 EDMONTON AB T6N 1H1 |
Tel: | N/A |
Website: | https://innovotech.ca |
IR: | See website |
Key People | ||
James Timourian Chairman of the Board, President, Chief Executive Officer, Company Secretary | Alan C. Savage Chief Financial Officer, Director |
Business Overview |
Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products. |
Financial Overview |
For the nine months ended 30 September 2023, Innovotech Inc revenues decreased 4% to C$842K. Net loss increased from C$53K to C$128K. Revenues reflect Rest Of World segment decrease of 18% to C$88K, Canada segment decrease of 36% to C$20K. Higher net loss reflects General and Administrative increase of 14% to C$704K (expense), Sales and Marketing increase from C$1K to C$24K (expense). |
Employees: | 16 as of Mar 13, 2012 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $4.55M as of Sep 30, 2023 |
Annual revenue (TTM): | $1.09M as of Sep 30, 2023 |
EBITDA (TTM): | -$0.18M as of Sep 30, 2023 |
Net annual income (TTM): | -$0.21M as of Sep 30, 2023 |
Free cash flow (TTM): | -$0.26M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 39,003,612 as of Feb 6, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |